The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
SPARC to receive 55% equity in Tiller Therapeutics
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE
Subscribe To Our Newsletter & Stay Updated
